金斯瑞生物科技：CARVYKTI 于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI is expected to generate net trade sales of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected net trade sales for CARVYKTI are approximately $524 million for the quarter ending September 30, 2025 [1]